Targeting opioid and neurokinin-1 receptors to treat alcoholism

Current Medicinal Chemistry

Volumn 18, Issue 28, 2011, Pages 4321-4334

  Rodriguez, F D ^a   Covenas R ^b  

^a Campus M de Unamuno ^*  (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Alcoholism; Neurokinin 1 receptor (NK1R) antagonists; Opioids; Reward; Substance P

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 2 BENZHYDRYL 3 (2 IODOBENZYLAMINO)QUINUCLIDINE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; 5 [[3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYL 1 PIPERIDINYL]METHYL] 1,2 DIHYDRO 3H 1,2,4 TRIAZOL 3 ONE; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; ACAMPROSATE; ALCOHOL; APREPITANT; BETA ENDORPHIN; BUPRENORPHINE; BUTORPHANOL; DAPITANT; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DISULFIRAM; DYNORPHIN A; KAPPA OPIATE RECEPTOR; L 709210; LY 686017; MEMANTINE; MORPHINE; MU OPIATE RECEPTOR; MU OPIATE RECEPTOR AGONIST; N ACETYLTRYPTOPHAN 3,5 BIS(TRIFLUOROMETHYL)BENZYL ESTER; NALMEFENE; NALOXONE; NALTREXAMINE DERIVATIVE; NALTREXONE; NALTRINDOLE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NOCICEPTIN RECEPTOR; NOLPITANTIUM; OPIATE RECEPTOR; OS 462; RP 73467; SUBSTANCE P; TL 319; UFP 102; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOFOPITANT;

ALCOHOLISM; BRAIN REGION; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HEADACHE; HUMAN; LIVER TOXICITY; NAUSEA; NEUROBIOLOGY; NONHUMAN; REVIEW; REWARD; RNA INTERFERENCE; VOMITING;

ALCOHOLISM; ANIMALS; HUMANS; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; PIPERIDINES; RECEPTORS, NEUROKININ-1; RECEPTORS, OPIOID; SUBSTANCE P;

EID: 80052917261     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986711797200444     Document Type: Review

References (214)

1. World Health Organization. Global status report on alcohol 2011. 2011.
2. Rehm, J.; Mathers, C.; Popova, S.; Thavorncharoensap, M.; Teerawattananon, Y.; Patra, J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet, 2009, 373(9682), 2223-2233.
3. Heilig, M.; Thorsell, A.; Sommer, W. H.; Hansson, A. C.; Ramchandani, V. A.; George, D. T.; Hommer, D.; Barr, C. S. Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci. Biobehav. Rev., 2010, 35(2), 334-344.
4. Ciccocioppo, R.; Gehlert, D. R.; Ryabinin, A.; Kaur, S.; Cippitelli, A.; Thorsell, A.; Le, A. D.; Hipskind, P. A.; Hamdouchi, C.; Lu, J.; Hembre, E. J.; Cramer, J.; Song, M.; McKinzie, D.; Morin, M.; Economidou, D.; Stopponi, S.; Cannella, N.; Braconi, S.; Kallupi, M.; de Guglielmo, G.; Massi, M.; George, D. T.; Gilman, J.; Hersh, J.; Tauscher, J. T.; Hunt, S. P.; Hommer, D.; Heilig, M. Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond. Alcohol, 2009, 43(7), 491-498.
5. Monti, P. M.; Rohsenow, D. J.; Rubonis, A. V.; Niaura, R. S.; Sirota, A. D.; Colby, S. M.; Abrams, D. B. Alcohol cue reactivity: effects of detoxification and extended exposure. J. Stud. Alcohol, 1993, 54(2), 235-245. (Pubitemid 23101830)
6. O'Brien, C. P. A range of research-based pharmacotherapies for addiction. Science, 1997, 278(5335), 66-70. (Pubitemid 27446273)
7. Volpicelli, J. R.; Alterman, A. I.; Hayashida, M.; O'Brien, C. P. Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry, 1992, 49(11), 876-880.
8. Leggio, L.; Cardone, S.; Ferrulli, A.; Kenna, G. A.; Diana, M.; Swift, R. M.; Addolorato, G. Turning the clock ahead: potential preclinical and clinical neuropharmacological targets for alcohol dependence. Curr. Pharm. Des., 2010, 16(19), 2159-2118.
9. Mutschler, J.; Grosshans, M.; Kiefer, F. A new pharmacological treatment option for alcohol dependence discovered in transnational study: neurokinin-1 receptor antagonist as a possible therapy for alcoholism? Neuropsychiatr., 2008, 22(4), 283-285.
10. Hughes, J.; Smith, T. W.; Kosterlitz, H. W.; Fothergill, L. A.; Morgan, B. A.; Morris, H. R. Identification of two related pentapeptides from the brain with potent opiate agonist activity. Nature, 1975, 258(5536), 577-580.
11. Simantov, R. and Snyder, S. H. Morphine-like peptides in mammalian brain: isolation, structure elucidation, and interactions with the opiate receptor. Proc. Natl. Acad. Sci. U. S. A., 1976, 73(7), 2515-2519.
12. Gianoulakis, C. Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr. Top. Med. Chem., 2009, 9(11), 999-1015.
13. Terenius, L. and Johansson, B. The opioid systems-panacea and nemesis. Biochem. Biophys. Res. Commun., 2010, 396(1), 140-142.
14. Zadina, J. E.; Hackler, L.; Ge, L. J.; Kastin, A. J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature, 1997, 386(6624), 499-502. (Pubitemid 27164076)
15. Trigo, J. M.; Martin-Garcia, E.; Berrendero, F.; Robledo, P.; Maldonado, R. The endogenous opioid system: a common substrate in drug addiction. Drug Alcohol Depend., 2010, 108(3), 183-194.
16. Simon, E. J. In search of the opiate receptor. Am. J. Med. Sci., 1973, 266(3), 160-168.
17. Terenius, L. Stereospecific interaction between narcotic analgesics and a synaptic plasm a membrane fraction of rat cerebral cortex. Acta Pharmacol. Toxicol. (Copenh), 1973, 32(3), 317-320.
18. Pert, C. B. and Snyder, S. H. Opiate receptor: demonstration in nervous tissue. Science, 1973, 179(77), 1011-1014.
19. Pert, C. B.; Pasternak, G.; Snyder, S. H. Opiate agonists and antagonists discriminated by receptor binding in brain. Science, 1973, 182(119), 1359-1361.
20. Martin, W. R.; Eades, C. G.; Thompson, J. A.; Huppler, R. E.; Gilbert, P. E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther., 1976, 197(3), 517-532.
21. Evans, C. J.; Keith, D. E., Jr; Morrison, H.; Magendzo, K.; Edwards, R. H. Cloning of a delta opioid receptor by functional expression. Science, 1992, 258(5090), 1952-1955.
22. Fukuda, K.; Kato, S.; Mori, K.; Nishi, M.; Takeshima, H. Primary structures and expression from cDNAs of rat opioid receptor delta- and mu-subtypes. FEBS Lett., 1993, 327(3), 311-314. (Pubitemid 23228574)
23. Kieffer, B. L.; Befort, K.; Gaveriaux-Ruff, C.; Hirth, C. G. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc. Natl. Acad. Sci. U. S. A., 1992, 89(24), 12048-12052. (Pubitemid 23004782)
24. Wang, J. B.; Imai, Y.; Eppler, C. M.; Gregor, P.; Spivak, C. E.; Uhl, G. R. mu opiate receptor: cDNA cloning and expression. Proc. Natl. Acad. Sci. U. S. A., 1993, 90(21), 10230-10234. (Pubitemid 23328286)
25. Yasuda, K.; Raynor, K.; Kong, H.; Breder, C. D.; Takeda, J.; Reisine, T.; Bell, G. I. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc. Natl. Acad. Sci. U. S. A., 1993, 90(14), 6736-6740. (Pubitemid 23207288)
26. Kane, B. E.; Svensson, B.; Ferguson, D. M. Molecular recognition of opioid receptor ligands. AAPS J., 2006, 8(1), E126-37.
27. Bodnar, R. J. Endogenous opiates and behavior: 2009. Peptides, 2010, 31(12), 2325-2359.
28. New, D. C. and Wong, Y. H. The ORL1 receptor: molecular pharmacology and signalling mechanisms. Neurosignals, 2002, 11(4), 197-212. (Pubitemid 37494399)
29. Dietis, N.; Guerrini, R.; Calo, G.; Salvadori, S.; Rowbotham, D. J.; Lambert, D. G. Simultaneous targeting of multiple opioid receptors: a strategy to improve side-effect profile. Br. J. Anaesth., 2009, 103(1), 38-49.
30. Meunier, J. C.; Mollereau, C.; Toll, L.; Suaudeau, C.; Moisand, C.; Alvinerie, P.; Butour, J. L.; Guillemot, J. C.; Ferrara, P.; Monsarrat, B. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature, 1995, 377(6549), 532-535.
31. Reinscheid, R. K.; Nothacker, H. P.; Bourson, A.; Ardati, A.; Henningsen, R. A.; Bunzow, J. R.; Grandy, D. K.; Langen, H.; Monsma, F. J., Jr; Civelli, O. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science, 1995, 270(5237), 792-794.
32. Pasternak, G. W. Multiple opiate receptors: deja vu all over again. Neuropharmacology, 2004, 47(Suppl 1), 312-323. (Pubitemid 39298274)
33. Cvejic, S. and Devi, L. A. Dimerization of the delta opioid receptor: implication for a role in receptor internalization. J. Biol. Chem., 1997, 272(43), 26959-26964. (Pubitemid 27452648)
34. van Rijn, R. M.; Whistler, J. L.; Waldhoer, M. Opioid-receptor- heteromerspecific trafficking and pharmacology. Curr. Opin. Pharmacol., 2010, 10(1), 73-79.
35. Bond, C.; LaForge, K. S.; Tian, M.; Melia, D.; Zhang, S.; Borg, L.; Gong, J.; Schluger, J.; Strong, J. A.; Leal, S. M.; Tischfield, J. A.; Kreek, M. J.; Yu, L. Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(16), 9608-9613. (Pubitemid 28506279)
36. Xuei, X.; Dick, D.; Flury-Wetherill, L.; Tian, H. J.; Agrawal, A.; Bierut, L.; Goate, A.; Bucholz, K.; Schuckit, M.; Nurnberger, J., Jr; Ischfield, J.; Kuperman, S.; Porjesz, B.; Begleiter, H.; Foroud, T.; Edenberg, H. J. Association of the kappa-opioid system with alcohol dependence. Mol. Psychiatry, 2006, 11(11), 1016-1024. (Pubitemid 44631644)
37. Arias, A. J.; Armeli, S.; Gelernter, J.; Covault, J.; Kallio, A.; Karhuvaara, S.; Koivisto, T.; Makela, R.; Kranzler, H. R. Effects of opioid receptor gene variation on targeted nalmefene treatment in heavy drinkers. Alcohol. Clin. Exp. Res., 2008, 32(7), 1159-1166.
38. Huang, J.; Young, B.; Pletcher, M. T.; Heilig, M.; Wahlestedt, C. Association between the nociceptin receptor gene (OPRL1) single nucleotide polymorphisms and alcohol dependence. Addict. Biol., 2008, 13(1), 88-94. (Pubitemid 351202141)
39. Mague, S. D. and Blendy, J. A. OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. Drug Alcohol Depend., 2010, 108(3), 172-182.
40. Law, P. Y.; Wong, Y. H.; Loh, H. H. Molecular mechanisms and regulation of opioid receptor signaling. Annu. Rev. Pharmacol. Toxicol., 2000, 40 389-430. (Pubitemid 30340688)
41. Rodriguez, F. D. The inhibition of [(3)H]inositol 1,4,5-trisphosphate binding by Ca(2+) is modified after long-term ethanol treatment and ethanol withdrawal. Addict. Biol., 2000, 5(2), 153-156. (Pubitemid 30229458)
42. Kreek, M. J. Overview and historical perspective of four papers presented on research related to the endogenous opioid system. Drug Alcohol Depend., 2010, 108(3), 195-199.
43. Sauriyal, D. S.; Jaggi, A. S.; Singh, N. Extending pharmacological spectrum of opioids beyond analgesia: Multifunctional aspects in different pathophysiological states. Neuropeptides, 2011, 45(3), 175-188.
44. Walwyn, W. M.; Miotto, K. A.; Evans, C. J. Opioid pharmaceuticals and addiction: the issues, and research directions seeking solutions. Drug Alcohol Depend., 2010, 108(3), 156-165.
45. Koob, G. F.; Kenneth Lloyd, G.; Mason, B. J. Development of pharmacotherapies for drug addiction: a Rosetta stone approach. Nat. Rev. Drug Discov., 2009, 8(6), 500-515.
46. Koob, G. F. and Volkow, N. D. Neurocircuitry of addiction. Neuropsychopharmacology, 2010, 35(1), 217-238.
47. Khachaturian, H.; Lewis, M. E.; Schäfer, M.; Watson, S. J. Anatomy of the CNS opioid systems. Trends Neurosci., 1985, 10, 111-119. (Pubitemid 15116145)
48. Mansour, A.; Khachaturian, H.; Lewis, M. E.; Akil, H.; Watson, S. J. Anatomy of CNS opioid receptors. Trends Neurosci., 1988, 11(7), 308-314.
49. Lewis, M. E.; Khachaturian, H.; Watson, S. J. Combined autoradiographicimmunocytochemical analysis of opioid receptors and opioid peptide neuronal systems in brain. Peptides, 1985, 6(Suppl 1), 37-47. (Pubitemid 16205913)
50. Mollereau, C. and Mouledous, L. Tissue distribution of the opioid receptorlike (ORL1) receptor. Peptides, 2000, 21(7), 907-917.
51. Gianoulakis, C. Endogenous opioids and addiction to alcohol and other rugs of abuse. Curr. Top. Med. Chem., 2009, 9(11), 999-1015.
52. Spanagel, R. Alcoholism: a systems approach from molecular physiology to addictive behavior. Physiol. Rev., 2009, 89(2), 649-705.
53. Haber, S. N. and Knutson, B. The reward circuit: linking primate anatomy and human imaging. Neuropsychopharmacology, 2010, 35(1), 4-26.
54. Koob, G. F. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction, 2006, 101(Suppl 1), 23-30. (Pubitemid 44199493)
55. Haber, S. N. and Rauch, S. L. Neurocircuitry: a window into the networks underlying neuropsychiatric disease. Neuropsychopharmacology, 2010, 35(1), 1-3.
56. Koob, G. F. Brain stress systems in the amygdala and addiction. Brain Res., 2009, 1293, 61-75.
57. Baek, M. N.; Jung, K. H.; Halder, D.; Choi, M. R.; Lee, B. H.; Lee, B. C.; Jung, M. H.; Choi, I. G.; Chung, M. K.; Oh, D. Y.; Chai, Y. G. Artificial microRNA-based neurokinin-1 receptor gene silencing reduces alcohol consumption in mice. Neurosci. Lett., 2010, 475(3), 124-128.
58. Kertes, E.; Laszlo, K.; Berta, B.; Lenard, L. Positive reinforcing effects of substance P in the rat globus pallidus revealed by conditioned place preference. Behav. Brain Res., 2010, 215(1), 152-155.
59. Sacharczuk, M.; Juszczak, G.; Swiergiel, A. H.; Jaszczak, K.; Lipkowski, A. W.; Sadowski, B. Alcohol reverses depressive and pronociceptive effects of chronic stress in mice with enhanced activity of the opioid system. Acta Neurobiol. Exp. (Wars), 2009, 69(4), 459-468.
60. Platt, D. M. and Bano, K. M. Opioid receptors and the discriminative stimulus effects of ethanol in squirrel monkeys: Mu and delta opioid receptor mechanisms. Eur. J. Pharmacol., 2011, 650(1), 233-239.
61. Bechtholt, A. J. and Cunningham, C. L. Ethanol-induced conditioned place preference is expressed through a ventral tegmental area dependent mechanism. Behav. Neurosci., 2005, 119(1), 213-223. (Pubitemid 40279511)
62. Clapp, P.; Bhave, S. V.; Hoffman, P. L. How Adaptation of the Brain to Alcohol Leads to Dependence: A Pharmacological Perspective. Alcohol Res. Health, 2008, 31(4), 310-339.
63. Vengeliene, V.; Bilbao, A.; Molander, A.; Spanagel, R. Neuropharmacology of alcohol addiction. Br. J. Pharmacol., 2008, 154(2), 299-315. (Pubitemid 351670598)
64. Jarjour, S.; Bai, L.; Gianoulakis, C. Effect of acute ethanol administration on the release of opioid peptides from the midbrain including the ventral tegmental area. Alcohol. Clin. Exp. Res., 2009, 33(6), 1033-1043.
65. Hall, F. S.; Sora, I.; Uhl, G. R. Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl), 2001, 154(1), 43-49. (Pubitemid 32186514)
66. Kovacs, K. M.; Szakall, I.; O'Brien, D.; Wang, R.; Vinod, K. Y.; Saito, M.; Simonin, F.; Kieffer, B. L.; Vadasz, C. Decreased oral self-administration of alcohol in kappa-opioid receptor knock-out mice. Alcohol. Clin. Exp. Res., 2005, 29(5), 730-738. (Pubitemid 40686541)
67. Roberts, A. J.; Gold, L. H.; Polis, I.; McDonald, J. S.; Filliol, D.; Kieffer, B. L.; Koob, G. F. Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol. Clin. Exp. Res., 2001, 25(9), 1249-1256. (Pubitemid 32868332)
68. van Rijn, R. M. and Whistler, J. L. The delta(1) opioid receptor is a heterodimer that opposes the actions of the delta(2) receptor on alcohol intake. Biol. Psychiatry, 2009, 66(8), 777-784.
69. Rada, P.; Barson, J. R.; Leibowitz, S. F.; Hoebel, B. G. Opioids in the hypothalamus control dopamine and acetylcholine levels in the nucleus accumbens. Brain Res., 2010, 1312, 1-9.
70. Barson, J. R.; Carr, A. J.; Soun, J. E.; Sobhani, N. C.; Rada, P.; Leibowitz, S. F.; Hoebel, B. G. Opioids in the hypothalamic paraventricular nucleus stimulate ethanol intake. Alcohol. Clin. Exp. Res., 2010, 34(2), 214-222.
71. Lasek, A. W.; Janak, P. H.; He, L.; Whistler, J. L.; Heberlein, U. Downregulation of mu opioid receptor by RNA interference in the ventral tegmental area reduces ethanol consumption in mice. Genes Brain Behav., 2007, 6(8), 728-735. (Pubitemid 350043944)
72. Ramachandra, V.; Kang, F.; Kim, C.; Nova, A. S.; Bajaj, A.; Scott Hall, F.; Uhl, G. R.; Gonzales, R. A. The Mu Opioid Receptor Is Not Involved in Ethanol-Stimulated Dopamine Release in the Ventral Striatum of C57BL/6J Mice. Alcohol. Clin. Exp. Res., 2011, 35(5), 929-938.
73. Margolis, E. B.; Fields, H. L.; Hjelmstad, G. O.; Mitchell, J. M. Delta-opioid receptor expression in the ventral tegmental area protects against elevated alcohol consumption. J. Neurosci., 2008, 28(48), 12672-12681.
74. Shippenberg, T. S.; Zapata, A.; Chefer, V. I. Dynorphin and the pathophysiology of drug addiction. Pharmacol. Ther., 2007, 116(2), 306-321. (Pubitemid 47454747)
75. Sakoori, K. and Murphy, N. P. Endogenous nociceptin (orphanin FQ) suppresses basal hedonic state and acute reward responses to methamphetamine and ethanol, but facilitates chronic responses. Neuropsychopharmacology, 2008, 33(4), 877-891. (Pubitemid 351252694)
76. Ciccocioppo, R.; Economidou, D.; Fedeli, A.; Angeletti, S.; Weiss, F.; Heilig, M.; Massi, M. Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats. Psychopharmacology (Berl), 2004, 172(2), 170-178. (Pubitemid 38388766)
77. Murphy, N. P. The nociceptin/orphanin FQ system as a target for treating alcoholism. CNS Neurol. Disord. Drug Targets, 2010, 9(1), 87-93.
78. Sommer, W.; Hyytia, P.; Kiianmaa, K. The alcohol-preferring AA and alcohol-avoiding ANA rats: neurobiology of the regulation of alcohol drinking. Addict. Biol., 2006, 11(3-4), 289-309. (Pubitemid 46696912)
79. Clapp, P.; Bhave, S. V.; Hoffman, P. L. How Adaptation of the Brain to Alcohol Leads to Dependence: A Pharmacological Perspective. Alcohol Res. Health, 2008, 31(4), 310-339.
80. Munoz, M. and Covenas, R. NK-1 receptor antagonists: a new paradigm in pharmacological therapy. Curr. Med. Chem., 2011, 18(12), 1820-1831.
81. Cuello, A. C. and Kanazawa, I. The distribution of substance P immunoreactive fibers in the rat central nervous system. J. Comp. Neurol., 1978, 178(1), 129-156.
82. Hokfelt, T.; Pernow, B.; Nilsson, G.; Wetterberg, L.; Goldstein, M.; Jeffcoate, S. L. Dense plexus of substance P immunoreactive nerve terminals in eminentia medialis of the primate hypothalamus. Proc. Natl. Acad. Sci. U. S. A., 1978, 75(2), 1013-1015. (Pubitemid 8298503)
83. Burgos, C.; Aguirre, J. A.; Alonso, J. R.; Covenas, R. Immunocytochemical study of substance P-like fibres and cell bodies in the cat diencephalon. J. Hirnforsch., 1988, 29(6), 651-657. (Pubitemid 19046442)
84. Mai, J. K.; Stephens, P. H.; Hopf, A.; Cuello, A. C. Substance P in the human brain. Neuroscience, 1986, 17(3), 709-739. (Pubitemid 16131267)
85. Acsady, L.; Katona, I.; Gulyas, A. I.; Shigemoto, R.; Freund, T. F. Immunostaining for substance P receptor labels GABAergic cells with distinct termination patterns in the hippocampus. J. Comp. Neurol., 1997, 378(3), 320-336. (Pubitemid 27061459)
86. Chen, L. W.; Cao, R.; Liu, H. L.; Ju, G.; Chan, Y. S. The striatal GABAergic neurons expressing substance P receptors in the basal ganglia of mice. Neuroscience, 2003, 119(4), 919-925. (Pubitemid 36776443)
87. Marksteiner, J.; Kaufmann, W.; Pfaller, K.; Sieghart, W.; Saria, A. Striatal efferents preferentially innervate neurons in the ventral pallidum containing GABAA receptor alpha 1 subunit-like immunoreactivity. Synapse, 1996, 23(2), 107-114.
88. Turner, A. J. Biochemical Society. Neurochemical Group. Neuropeptides and their peptidases. Ellis Horwood series in Biomedicine, 1987, 295 pages.
89. Holmes, A.; Heilig, M.; Rupniak, N. M.; Steckler, T.; Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci., 2003, 24(11), 580-588. (Pubitemid 37357142)
90. Ebner, K.; Rupniak, N. M.; Saria, A.; Singewald, N. Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc. Natl. Acad. Sci. U. S. A., 2004, 101(12), 4280-4285. (Pubitemid 38405920)
91. Ebner, K.; Muigg, P.; Singewald, G.; Singewald, N. Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann. N. Y. Acad. Sci., 2008, 1144, 61-73.
92. Ebner, K.; Singewald, G. M.; Whittle, N.; Ferraguti, F.; Singewald, N. Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5-HT transmission. Neuropsychopharmacology, 2008, 33(8), 1929-1941. (Pubitemid 351832607)
93. Ebner, K. and Singewald, N. Stress-induced release of substance P in the locus coeruleus modulates cortical noradrenaline release. Naunyn Schmiedebergs Arch. Pharmacol., 2007, 376(1-2), 73-82.
94. Unger, T.; Rascher, W.; Schuster, C.; Pavlovitch, R.; Schomig, A.; Dietz, R.; Ganten, D. Central blood pressure effects of substance P and angiotensin II: role of the sympathetic nervous system and vasopressin. Eur. J. Pharmacol., 1981, 71(1), 33-42. (Pubitemid 11112563)
95. Hershey, A. D.; Polenzani, L.; Woodward, R. M.; Miledi, R.; Krause, J. E. Molecular and genetic characterization, functional expression, and mRNA expression patterns of a rat substance P receptor. Ann. N. Y. Acad. Sci., 1991, 632, 63-78.
96. Quartara, L. and Maggi, C. A. The tachykinin NK1 receptor. Part II: Distribution and pathophysiological roles. Neuropeptides, 1998, 32(1), 1-49. (Pubitemid 28167857)
97. V Euler, U. S. and Gaddum, J. H. An unidentified depressor substance in certain tissue extracts. J. Physiol., 1931, 72(1), 74-87.
98. Pernow, B. Substance P. Pharmacol. Rev., 1983, 35(2), 85-141. (Pubitemid 13016042)
99. Hokfelt, T.; Pernow, B.; Wahren, J. Substance P: a pioneer amongst neuropeptides. J. Intern. Med., 2001, 249(1), 27-40. (Pubitemid 32147090)
100. Rupniak, N. M.; Carlson, E.; Boyce, S.; Webb, J. K.; Hill, R. G. Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain, 1996, 67(1), 189-195. (Pubitemid 26319652)
101. Kramer, M. S.; Cutler, N.; Feighner, J.; Shrivastava, R.; Carman, J.; Sramek, J. J.; Reines, S. A.; Liu, G.; Snavely, D.; Wyatt-Knowles, E.; Hale, J. J.; Mills, S. G.; MacCoss, M.; Swain, C. J.; Harrison, T.; Hill, R. G.; Hefti, F.; Scolnick, E. M.; Cascieri, M. A.; Chicchi, G. G.; Sadowski, S.; Williams, A. R.; Hewson, L.; Smith, D.; Carlson, E. J.; Hargreaves, R. J.; Rupniak, N. M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 1998, 281(5383), 1640-1645. (Pubitemid 28435572)
102. Samsam, M.; Covenas, R.; Ahangari, R.; Yajeya, J.; Narvaez, J. A.; Tramu, G. Simultaneous depletion of neurokinin A, substance P and calcitonin generelated peptide from the caudal trigeminal nucleus of the rat during electrical stimulation of the trigeminal ganglion. Pain, 2000, 84(2-3), 389-395. (Pubitemid 30074242)
103. Harrison, S. and Geppetti, P. Substance p. Int. J. Biochem. Cell Biol., 2001, 33(6), 555-576. (Pubitemid 32510811)
104. Bang, R.; Sass, G.; Kiemer, A. K.; Vollmar, A. M.; Neuhuber, W. L.; Tiegs, G. Neurokinin-1 receptor antagonists CP-96,345 and L-733,060 protect mice from cytokine-mediated liver injury. J. Pharmacol. Exp. Ther., 2003, 305(1), 31-39. (Pubitemid 36373833)
105. Varty, G. B.; Cohen-Williams, M. E.; Hunter, J. C. The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav. Pharmacol., 2003, 14(1), 87-95. (Pubitemid 36279029)
106. Munoz, M.; Perez, A.; Rosso, M.; Zamarriego, C.; Rosso, R. Antitumoral action of the neurokinin-1 receptor antagonist L-733 060 on human melanoma cell lines. Melanoma Res., 2004, 14(3), 183-188. (Pubitemid 38879579)
107. Munoz, M.; Rosso, M.; Perez, A.; Covenas, R.; Rosso, R.; Zamarriego, C.; Piruat, J. I. The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides, 2005, 39(4), 427-432. (Pubitemid 41073623)
108. Munoz, M.; Rosso, M.; Perez, A.; Covenas, R.; Rosso, R.; Zamarriego, C.; Soult, J. A.; Montero, I. Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest. Ophthalmol. Vis. Sci., 2005, 46(7), 2567-2570. (Pubitemid 43119507)
109. Munoz, M.; Rosso, M.; Covenas, R. The NK-1 Receptor: A New Target in Cancer Therapy. Curr. Drug Targets, 2011, 12(6), 909-921 .
110. Munoz, M. and Covenas, R. Neurokinin-1 receptor: a new promising target in the treatment of cancer. Discov. Med., 2010, 10(53), 305-313.
111. George, D. T.; Gilman, J.; Hersh, J.; Thorsell, A.; Herion, D.; Geyer, C.; Peng, X.; Kielbasa, W.; Rawlings, R.; Brandt, J. E.; Gehlert, D. R.; Tauscher, J. T.; Hunt, S. P.; Hommer, D.; Heilig, M. Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science, 2008, 319(5869), 1536-1539. (Pubitemid 351398184)
112. Quartara, L. and Maggi, C. A. The tachykinin NK1 receptor. Part I: ligands and mechanisms of cellular activation. Neuropeptides, 1997, 31(6), 537-563. (Pubitemid 28037471)
113. Macdonald, S. G. and Boyd, N. D. Regulation of substance P receptor affinity by guanine nucleotide-binding proteins. J. Neurochem., 1989, 53(1), 264-272. (Pubitemid 19158138)
114. Wolf, S. S.; Moody, T. W.; Quirion, R.; O'Donohue, T. L. Biochemical characterization and autoradiographic localization of central substance P receptors using [125I]physalaemin. Brain Res., 1985, 332(2), 299-307. (Pubitemid 15108000)
115. Dam, T. V. and Quirion, R. Pharmacological characterization and autoradiographic localization of substance P receptors in guinea pig brain. Peptides, 1986, 7(5), 855-864. (Pubitemid 17182354)
116. Danks, J. A.; Rothman, R. B.; Cascieri, M. A.; Chicchi, G. G.; Liang, T.; Herkenham, M. A comparative autoradiographic study of the distributions of substance P and eledoisin binding sites in rat brain. Brain Res., 1986, 385(2), 273-281. (Pubitemid 16006841)
117. Saffroy, M.; Beaujouan, J. C.; Torrens, Y.; Besseyre, J.; Bergstrom, L.; Glowinski, J. Localization of tachykinin binding sites (NK1, NK2, NK3 ligands) in the rat brain. Peptides, 1988, 9(2), 227-241. (Pubitemid 19260226)
118. Maeno, H.; Kiyama, H.; Tohyama, M. Distribution of the substance P receptor (NK-1 receptor) in the central nervous system. Brain Res. Mol. Brain Res., 1993, 18(1-2), 43-58.
119. Nakaya, Y.; Kaneko, T.; Shigemoto, R.; Nakanishi, S.; Mizuno, N. Immunohistochemical localization of substance P receptor in the central nervous system of the adult rat. J. Comp. Neurol., 1994, 347(2), 249-274. (Pubitemid 24273427)
120. Whitty, C. J.; Walker, P. D.; Goebel, D. J.; Poosch, M. S.; Bannon, M. J. Quantitation, cellular localization and regulation of neurokinin receptor gene expression within the rat substantia nigra. Neuroscience, 1995, 64(2), 419-425.
121. Munoz, M.; Rosso, M.; Covenas, R. A new frontier in the treatment of cancer: NK-1 receptor antagonists. Curr. Med. Chem., 2010, 17(6), 504-516.
122. Mitsuhashi, M.; Ohashi, Y.; Shichijo, S.; Christian, C.; Sudduth-Klinger, J.; Harrowe, G.; Payan, D. G. Multiple intracellular signaling pathways of the neuropeptide substance P receptor. J. Neurosci. Res., 1992, 32(3), 437-443.
123. Nakajima, Y.; Tsuchida, K.; Negishi, M.; Ito, S.; Nakanishi, S. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cyclic AMP cascades in transfected Chinese hamster ovary cells. J. Biol. Chem., 1992, 267(4), 2437-2442.
124. Takeda, Y.; Blount, P.; Sachais, B. S.; Hershey, A. D.; Raddatz, R.; Krause, J. E. Ligand binding kinetics of substance P and neurokinin A receptors stably expressed in Chinese hamster ovary cells and evidence for differential stimulation of inositol 1,4,5-trisphosphate and cyclic AMP second messenger responses. J. Neurochem., 1992, 59(2), 740-745.
125. Seabrook, G. R. and Fong, T. M. Thapsigargin blocks the mobilisation of intracellular calcium caused by activation of human NK1 (long) receptors expressed in Chinese hamster ovary cells. Neurosci. Lett., 1993, 152(1-2), 9-12. (Pubitemid 23149300)
126. Garcia, M.; Sakamoto, K.; Shigekawa, M.; Nakanishi, S.; Ito, S. Multiple mechanisms of arachidonic acid release in Chinese hamster ovary cells transfected with cDNA of substance P receptor. Biochem. Pharmacol., 1994, 48(9), 1735-1741. (Pubitemid 24338999)
127. Mochizuki-Oda, N.; Nakajima, Y.; Nakanishi, S.; Ito, S. Characterization of the substance P receptor-mediated calcium influx in cDNA transfected Chinese hamster ovary cells. A possible role of inositol 1,4,5-trisphosphate in calcium influx. J. Biol. Chem., 1994, 269(13), 9651-9658.
128. Grady, E. F.; Garland, A. M.; Gamp, P. D.; Lovett, M.; Payan, D. G.; Bunnett, N. W. Delineation of the endocytic pathway of substance P and its seven-transmembrane domain NK1 receptor. Mol. Biol. Cell, 1995, 6(5), 509-524.
129. Bowden, J. J.; Garland, A. M.; Baluk, P.; Lefevre, P.; Grady, E. F.; Vigna, S. R.; Bunnett, N. W.; McDonald, D. M. Direct observation of substance Pinduced internalization of neurokinin 1 (NK1) receptors at sites of inflammation. Proc. Natl. Acad. Sci. U. S. A., 1994, 91(19), 8964-8968.
130. Garland, A. M.; Grady, E. F.; Payan, D. G.; Vigna, S. R.; Bunnett, N. W. Agonist-induced internalization of the substance P (NK1) receptor expressed in epithelial cells. Biochem. J., 1994, 303 (Pt 1), 177-186. (Pubitemid 24302916)
131. Mantyh, P. W.; Allen, C. J.; Ghilardi, J. R.; Rogers, S. D.; Mantyh, C. R.; Liu, H.; Basbaum, A. I.; Vigna, S. R.; Maggio, J. E. Rapid endocytosis of a G protein-coupled receptor: substance P evoked internalization of its receptor in the rat striatum in vivo. Proc. Natl. Acad. Sci. U. S. A., 1995, 92(7), 2622-2626.
132. Mantyh, P. W.; Hunt, S. P.; Maggio, J. E. Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand. Brain Res., 1984, 307(1-2), 147-165. (Pubitemid 14094573)
133. Kramer, M. S.; Cutler, N.; Feighner, J.; Shrivastava, R.; Carman, J.; Sramek, J. J.; Reines, S. A.; Liu, G.; Snavely, D.; Wyatt-Knowles, E.; Hale, J. J.; Mills, S. G.; MacCoss, M.; Swain, C. J.; Harrison, T.; Hill, R. G.; Hefti, F.; Scolnick, E. M.; Cascieri, M. A.; Chicchi, G. G.; Sadowski, S.; Williams, A. R.; Hewson, L.; Smith, D.; Carlson, E. J.; Hargreaves, R. J.; Rupniak, N. M. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 1998, 281(5383), 1640-1645. (Pubitemid 28435572)
134. Kushner, M. G.; Abrams, K.; Borchardt, C. The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin. Psychol. Rev., 2000, 20(2), 149-171. (Pubitemid 30100430)
135. Teixeira, R. M.; Santos, A. R.; Ribeiro, S. J.; Calixto, J. B.; Rae, G. A.; De Lima, T. C. Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur. J. Pharmacol., 1996, 311(1), 7-14. (Pubitemid 26298493)
136. Elliott, P. J. Place aversion induced by the substance P analogue, dimethyl-C7, is not state dependent: implication of substance P in aversion. Exp. Brain Res., 1988, 73(2), 354-356.
137. Ballard, T. M.; Sanger, S.; Higgins, G. A. Inhibition of shock-induced foot tapping behaviour in the gerbil by a tachykinin NK1 receptor antagonist. Eur. J. Pharmacol., 2001, 412(3), 255-264. (Pubitemid 32144941)
138. Papp, M.; Vassout, A.; Gentsch, C. The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav. Brain Res., 2000, 115(1), 19-23.
139. Rupniak, N. M. Elucidating the antidepressant actions of substance P (NK1 receptor) antagonists. Curr. Opin. Investig Drugs, 2002, 3(2), 257-261. (Pubitemid 34456083)
140. Rupniak, N. M.; Carlson, E. J.; Webb, J. K.; Harrison, T.; Porsolt, R. D.; Roux, S.; de Felipe, C.; Hunt, S. P.; Oates, B.; Wheeldon, A. Comparison of the phenotype of NK1R-/-mice with pharmacological blockade of the substance P (NK1 ) receptor in assays for antidepressant and anxiolytic drugs. Behav. Pharmacol., 2001, 12(6-7), 497-508. (Pubitemid 33152274)
141. Santarelli, L.; Gobbi, G.; Debs, P. C.; Sibille, E. T.; Blier, P.; Hen, R.; Heath, M. J. Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc. Natl. Acad. Sci. U. S. A., 2001, 98(4), 1912-1917. (Pubitemid 32165597)
142. Varty, G. B.; Cohen-Williams, M. E.; Morgan, C. A.; Pylak, U.; Duffy, R. A.; Lachowicz, J. E.; Carey, G. J.; Coffin, V. L. The gerbil elevated plusmaze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology, 2002, 27(3), 371-379. (Pubitemid 35253785)
143. File, S. E. Anxiolytic action of a neurokinin1 receptor antagonist in the social interaction test. Pharmacol. Biochem. Behav., 1997, 58(3), 747-752. (Pubitemid 27438133)
144. Nikolaus, S.; Huston, J. P.; Hasenohrl, R. U. The neurokinin-1 receptor antagonist WIN51,708 attenuates the anxiolytic-like effects of ventralpallidal substance P injection. Neuroreport, 1999, 10(11), 2293-2296. (Pubitemid 29367926)
145. Nikolaus, S.; Huston, J. P.; Hasenohrl, R. U. Reinforcing effects of neurokinin substance P in the ventral pallidum: mediation by the tachykinin NK1 receptor. Eur. J. Pharmacol., 1999, 370(2), 93-99. (Pubitemid 29185094)
146. Nikolaus, S.; Huston, J. P.; Hasenohrl, R. U. Anxiolytic-like effects in rats produced by ventral pallidal injection of both N- and C-terminal fragments of substance P. Neurosci. Lett., 2000, 283(1), 37-40. (Pubitemid 30145491)
147. Carletti, R.; Corsi, M.; Melotto, S.; Caberlotto, L. Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur. J. Neurosci., 2005, 21(6), 1712-1718. (Pubitemid 40646616)
148. Holmes, A.; Heilig, M.; Rupniak, N. M.; Steckler, T.; Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci., 2003, 24(11), 580-588. (Pubitemid 37357142)
149. Seneviratne, C.; Ait-Daoud, N.; Ma, J. Z.; Chen, G.; Johnson, B. A.; Li, M. D. Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. Neuropsychopharmacology, 2009, 34(11), 2442-2449.
150. Gadd, C. A.; Murtra, P.; De Felipe, C.; Hunt, S. P. Neurokinin-1 receptorexpressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J. Neurosci., 2003, 23(23), 8271-8280. (Pubitemid 37129644)
151. Ripley, T. L.; Gadd, C. A.; De Felipe, C.; Hunt, S. P.; Stephens, D. N. Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors. Neuropharmacology, 2002, 43(8), 1258-1268. (Pubitemid 36084436)
152. Steensland, P.; Simms, J. A.; Nielsen, C. K.; Holgate, J.; Bito-Onon, J. J.; Bartlett, S. E. The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol. PLoS One, 2010, 5(9), e12527.
153. Thorsell, A.; Schank, J. R.; Singley, E.; Hunt, S. P.; Heilig, M. Neurokinin-1 receptors (NK1R:s), alcohol consumption, and alcohol reward in mice. Psychopharmacology (Berl), 2010, 209(1), 103-111.
154. Commons, K. G. Neuronal pathways linking substance P to drug addiction and stress. Brain Res., 2010, 1314, 175-182.
155. Schuckit, M. A. and Hesselbrock, V. Alcohol dependence and anxiety disorders: what is the relationship? Am. J. Psychiatry, 1994, 151(12), 1723-1734. (Pubitemid 24370891)
156. Yang, A. R.; Yi, H. S.; Mamczarz, J.; June, H. L.,Jr; Hwang, B. H.; June HL, S. Deficits in substance P mRNA levels in the CeA are inversely associated with alcohol-motivated responding. Synapse, 2009, 63(11), 972-981.
157. Hwang, B. H.; Stewart, R. B.; Lumeng, L.; Li, T. K. The down-regulation of corticotropin releasing factor gene expression in the central nucleus of the amygdala is associated with high alcohol preference and anxiety in alcoholpreferring (P) rats. So. Neurosci. Abstr., 2001, 27, 732.11.
158. McBride, W. J. Central nucleus of the amygdala and the effects of alcohol and alcohol-drinking behavior in rodents. Pharmacol. Biochem. Behav., 2002, 71(3), 509-515. (Pubitemid 34117719)
159. Pandey, S. C.; Zhang, H.; Roy, A.; Xu, T. Deficits in amygdaloid cAMPresponsive element-binding protein signaling play a role in genetic predisposition to anxiety and alcoholism. J. Clin. Invest., 2005, 115(10), 2762-2773. (Pubitemid 41434403)
160. Koob, G. F. Neurobiology of addiction. Toward the development of new therapies. Ann. N. Y. Acad. Sci., 2000, 909, 170-185. (Pubitemid 30462039)
161. Koob, G. F. and Le Moal, M. Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat. Neurosci., 2005, 8(11), 1442-1444. (Pubitemid 41573653)
162. Pompei, P.; Angeletti, S.; Ciccocioppo, R.; Colombo, G.; Gessa, G. L.; Massi, M. Preprotachykinin-A gene expression in the forebrain of Sardinian alcohol-preferring and -nonpreferring rats. Brain Res. Mol. Brain Res., 1998, 56(1-2), 277-280. (Pubitemid 28271685)
163. Slawecki, C. J.; Jimenez-Vasquez, P.; Mathe, A. A.; Ehlers, C. L. Effect of ethanol on brain neuropeptides in adolescent and adult rats. J. Stud. Alcohol, 2005, 66(1), 46-52. (Pubitemid 40381600)
164. Scarrone, S.; Cappelli, A.; Cupello, A.; Matarrese, M.; Moresco, R. M.; Fazio, F. Ethanol inhibits the binding of substance P to rat brain cortex NK1 receptors. Neurochem. Res., 2003, 28(8), 1159-1162. (Pubitemid 36734546)
165. Minami, K.; Shiraishi, M.; Uezono, Y.; Ueno, S.; Shigematsu, A. The inhibitory effects of anesthetics and ethanol on substance P receptors expressed in Xenopus oocytes. Anesth. Analg., 2002, 94(1), 79-83. (Pubitemid 34038723)
166. Slawecki, C. J.; Jimenez-Vasquez, P.; Mathe, A. A.; Ehlers, C. L. Substance P and neurokinin levels are decreased in the cortex and hypothalamus of alcohol-preferring (P) rats. J. Stud. Alcohol, 2001, 62(6), 736-740. (Pubitemid 34118926)
167. Nikolaev, S. V.; Bychkov, E. R.; Lebedev, A. A.; Dambinova, S. A. Mechanisms of the influences of the central administration of substance P on ethanol consumption in chronically alcoholic rats. Neurosci. Behav. Physiol., 2003, 33(9), 905-909. (Pubitemid 38129922)
168. Oswald, L. M. and Wand, G. S. Opioids and alcoholism. Physiol. Behav., 2004, 81(2), 339-358. (Pubitemid 38670094)
169. Ciccocioppo, R.; Economidou, D.; Rimondini, R.; Sommer, W.; Massi, M.; Heilig, M. Buprenorphine reduces alcohol drinking through activation of the nociceptin/orphanin FQ-NOP receptor system. Biol. Psychiatry, 2007, 61(1), 4-12. (Pubitemid 44855733)
170. Kaste, K.; Kivinummi, T.; Piepponen, T. P.; Kiianmaa, K.; Ahtee, L. Differences in basal and morphine-induced FosB/DeltaFosB and pCREB immunoreactivities in dopaminergic brain regions of alcohol-preferring AA and alcohol-avoiding ANA rats. Pharmacol. Biochem. Behav., 2009, 92(4), 655-662.
171. Ojanen, S. P.; Hyytia, P.; Kiianmaa, K. Enhanced morphine-induced ethanol drinking in alcohol-preferring alko alcohol rats sensitized to morphine. Alcohol. Clin. Exp. Res., 2006, 30(4), 621-629.
172. Sabino, V.; Cottone, P.; Steardo, L.; Schmidhammer, H.; Zorrilla, E. P. 14-Methoxymetopon, a highly potent mu opioid agonist, biphasically affects ethanol intake in Sardinian alcohol-preferring rats. Psychopharmacology (Berl), 2007, 192(4), 537-546. (Pubitemid 46870748)
173. Breslin, F. J.; Johnson, B. A.; Lynch, W. J. Effect of topiramate treatment on ethanol consumption in rats. Psychopharmacology (Berl), 2010, 207(4), 529-534.
174. Hopf, F. W.; Simms, J. A.; Chang, S. J.; Seif, T.; Bartlett, S. E.; Bonci, A. Chlorzoxazone, an SK-Type Potassium Channel Activator Used in Humans, Reduces Excessive Alcohol Intake in Rats. Biol. Psychiatry, 2010, 69(7), 618-624.
175. Rodriguez-Arias, M.; Aguilar, M. A.; Manzanedo, C.; Minarro, J. Preclinical evidence of new opioid modulators for the treatment of addiction. Expert Opin. Investig. Drugs, 2010, 19(8), 977-994.
176. Mann, K. and Hermann, D. Individualised treatment in alcohol-dependent patients. Eur. Arch. Psychiatry Clin. Neurosci., 2010, 260 (Suppl 2), S116-20.
177. Rosner, S.; Hackl-Herrwerth, A.; Leucht, S.; Vecchi, S.; Srisurapanont, M.; Soyka, M. Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev., 2010, 12, CD001867.
178. Ghirmai, S.; Azar, M. R.; Cashman, J. R. Synthesis and pharmacological evaluation of 6-naltrexamine analogs for alcohol cessation. Bioorg. Med. Chem., 2009, 17(18), 6671-6681.
179. De Sousa, A. The pharmacotherapy of alcohol dependence: a state of the art review. Mens. Sana Monogr., 2010, 8(1), 69-82.
180. Kuzmin, A.; Stenback, T.; Liljequist, S. Memantine enhances the inhibitory effects of naltrexone on ethanol consumption. Eur. J. Pharmacol., 2008, 584(2-3), 352-356.
181. Oslin, D. W.; Berrettini, W.; Kranzler, H. R.; Pettinati, H.; Gelernter, J.; Volpicelli, J. R.; O'Brien, C. P. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology, 2003, 28(8), 1546-1552. (Pubitemid 41070891)
182. Ghirmai, S.; Azar, M. R.; Polgar, W. E.; Berzetei-Gurske, I.; Cashman, J. R. Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents. J. Med. Chem., 2008, 51(6), 1913-1924. (Pubitemid 351438873)
183. Soyka, M. and Rosner, S. Nalmefene for treatment of alcohol dependence. Expert Opin. Investig. Drugs, 2010, 19(11), 1451-1459.
184. Nealey, K. A.; Smith, A. W.; Davis, S. M.; Smith, D. G.; Walker, B. M. Kappa-Opioid Receptors are Implicated in the Increased Potency of Intra-Accumbens Nalmefene in Ethanol-Dependent Rats. Neuropharmacology, 2011, 61(1-2), 35-42.
185. Karhuvaara, S.; Simojoki, K.; Virta, A.; Rosberg, M.; Loyttyniemi, E.; Nurminen, T.; Kallio, A.; Makela, R. Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized doubleblind placebo-controlled multicenter study. Alcohol. Clin. Exp. Res., 2007, 31(7), 1179-1187. (Pubitemid 46934385)
186. Li, Q.; Okada, Y.; Marczak, E.; Wilson, W. A.; Lazarus, L. H.; Swartzwelder, H. S. The novel micro-opioid receptor antagonist, [N-allyl-Dmt(1)]endomorphin-2, attenuates the enhancement of GABAergic neurotransmission by ethanol. Alcohol Alcohol., 2009, 44(1), 13-19.
187. Varaschin, R. K. and Morato, G. S. Selective mu- and kappa-opioid receptor antagonists administered into the nucleus accumbens interfere with rapid tolerance to ethanol in rats. Psychopharmacology (Berl), 2009, 206(1), 85
188. Sperling, R. E.; Gomes, S. M.; Sypek, E. I.; Carey, A. N.; McLaughlin, J. P. Endogenous kappa-opioid mediation of stress-induced potentiation of ethanol-conditioned place preference and self-administration. Psychopharmacology (Berl), 2010, 210(2), 199-209.
189. van Rijn, R. M.; Whistler, J. L.; Waldhoer, M. Opioid-receptor- heteromerspecific trafficking and pharmacology. Curr. Opin. Pharmacol., 2010, 10(1), 73-79.
190. Nielsen, C. K.; Simms, J. A.; Pierson, H. B.; Li, R.; Saini, S. K.; Ananthan, S.; Bartlett, S. E. A novel delta opioid receptor antagonist, SoRI-9409, produces a selective and long-lasting decrease in ethanol consumption in heavydrinking rats. Biol. Psychiatry, 2008, 64(11), 974-981.
191. Fulton, B. S.; Knapp, B. L.; Bidlack, J. M.; Neumeyer, J. L. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg. Med. Chem. Lett., 2010, 20(5), 1507-1509.
192. Decker, M.; Si, Y. G.; Knapp, B. I.; Bidlack, J. M.; Neumeyer, J. L. Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J. Med. Chem., 2010, 53(1), 402-418.
193. Ciccocioppo, R.; Gehlert, D. R.; Ryabinin, A.; Kaur, S.; Cippitelli, A.; Thorsell, A.; Le, A. D.; Hipskind, P. A.; Hamdouchi, C.; Lu, J.; Hembre, E. J.; Cramer, J.; Song, M.; McKinzie, D.; Morin, M.; Economidou, D.; Stopponi, S.; Cannella, N.; Braconi, S.; Kallupi, M.; de Guglielmo, G.; Massi, M.; George, D. T.; Gilman, J.; Hersh, J.; Tauscher, J. T.; Hunt, S. P.; Hommer, D.; Heilig, M. Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond. Alcohol, 2009, 43(7), 491-498.
194. Economidou, D.; Fedeli, A.; Fardon, R. M.; Weiss, F.; Massi, M.; Ciccocioppo, R. Effect of novel nociceptin/orphanin FQ-NOP receptor ligands on ethanol drinking in alcohol-preferring msP rats. Peptides, 2006, 27(12), 3299-3306. (Pubitemid 44738195)
195. Economidou, D.; Cippitelli, A.; Stopponi, S.; Braconi, S.; Clementi, S.; Ubaldi, M.; Martin-Fardon, R.; Weiss, F.; Massi, M.; Ciccocioppo, R. Activation of Brain NOP Receptors Attenuates Acute and Protracted Alcohol Withdrawal Symptoms in the Rat. Alcohol. Clin. Exp. Res., 2011, 35(4), 747-755.
196. Chiou, L. C.; Liao, Y. Y.; Fan, P. C.; Kuo, P. H.; Wang, C. H.; Riemer, C.; Prinssen, E. P. Nociceptin/orphanin FQ peptide receptors: pharmacology and clinical implications. Curr. Drug Targets, 2007, 8(1), 117-135. (Pubitemid 46043903)
197. Pergolizzi, J.; Aloisi, A. M.; Dahan, A.; Filitz, J.; Langford, R.; Likar, R.; Mercadante, S.; Morlion, B.; Raffa, R. B.; Sabatowski, R.; Sacerdote, P.; Torres, L. M.; Weinbroum, A. A. Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract., 2010, 10(5), 428-450.
198. Zaveri, N. T. The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications. Curr. Top. Med. Chem., 2011, 11(9), 1151-1156.
199. Khroyan, T. V.; Polgar, W. E.; Cami-Kobeci, G.; Husbands, S. M.; Zaveri, N. T.; Toll, L. The First Universal Opioid Ligand, (2S)-2-[(5R,6R,7R,14S)-N- cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy -6-methoxymorphinan-7-yl]-3,3- dimethylpentan-2-ol (BU08028): Characterization of the In vitro Profile and In vivo Behavioral Effects in Mouse Models of Acute Pain and Cocaine-Induced Reward. J. Pharmacol. Exp. Ther., 2011, 336(3), 952-961.
200. Maggi, C. A.; Patacchini, R.; Rovero, P.; Giachetti, A. Tachykinin receptors and tachykinin receptor antagonists. J. Auton. Pharmacol., 1993, 13(1), 23-93. (Pubitemid 23054476)
201. Regoli, D.; Boudon, A.; Fauchere, J. L. Receptors and antagonists for substance P and related peptides. Pharmacol. Rev., 1994, 46(4), 551-599.
202. Lee, C. M.; Campbell, N. J.; Williams, B. J.; Iversen, L. L. Multiple tachykinin binding sites in peripheral tissues and in brain. Eur. J. Pharmacol., 1986, 130(3), 209-217. (Pubitemid 17193205)
203. Furmark, T.; Appel, L.; Michelgard, A.; Wahlstedt, K.; Ahs, F.; Zancan, S.; Jacobsson, E.; Flyckt, K.; Grohp, M.; Bergstrom, M.; Pich, E. M.; Nilsson, L. G.; Bani, M.; Langstrom, B.; Fredrikson, M. Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol. Psychiatry, 2005, 58(2), 132-142. (Pubitemid 41008130)
204. Rost, K.; Fleischer, F.; Nieber, K. Neurokinin 1 receptor antagonists-between hope and disappointment]. Med. Monatsschr. Pharm., 2006, 29(6), 200-205. (Pubitemid 44178381)
205. Hargreaves, R.; Ferreira, J. C.; Hughes, D.; Brands, J.; Hale, J.; Mattson, B.; Mills, S. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann. N. Y. Acad. Sci., 2011, 1222(1), 40-48.
206. Diemunsch, P. and Grelot, L. Potential of substance P antagonists as antiemetics. Drugs, 2000, 60(3), 533-546.
207. Gilman, J. M. and Hommer, D. W. Modulation of brain response to emotional images by alcohol cues in alcohol-dependent patients. Addict. Biol., 2008, 13(3-4), 423-434.
208. Camara, P. R.; Ferraz, G. J.; Franco-Penteado, C. F.; Sbragia-Neto, L.; Meirelles, L. R.; Teixeira, S. A.; Muscara, M. N.; Velloso, L. A.; Antunes, E.; Ferraz, J. G. Ablation of primary afferent neurons by neonatal capsaicin treatment reduces the susceptibility of the portal hypertensive gastric mucosa to ethanol-induced injury in cirrhotic rats. Eur. J. Pharmacol., 2008, 589(1-3), 245-250.
209. Gazzieri, D.; Trevisani, M.; Springer, J.; Harrison, S.; Cottrell, G. S.; Andre, E.; Nicoletti, P.; Massi, D.; Zecchi, S.; Nosi, D.; Santucci, M.; Gerard, N. P.; Lucattelli, M.; Lungarella, G.; Fischer, A.; Grady, E. F.; Bunnett, N. W.; Geppetti, P. Substance P released by TRPV1-expressing neurons produces reactive oxygen species that mediate ethanol-induced gastric injury. Free Radic. Biol. Med., 2007, 43(4), 581-589. (Pubitemid 47058237)
210. Haile, C. N.; Kosten, T. A.; Kosten, T. R. Pharmacogenetic treatments for drug addiction: alcohol and opiates. Am. J. Drug Alcohol Abuse, 2008, 34(4), 355-381. (Pubitemid 351913747)
211. Kranzler, H. R. and Edenberg, H. J. Pharmacogenetics of alcohol and alcohol dependence treatment. Curr. Pharm. Des., 2010, 16(19), 2141-2148.
212. Tidey, J. W.; Monti, P. M.; Rohsenow, D. J.; Gwaltney, C. J.; Miranda, R.,Jr; McGeary, J. E.; MacKillop, J.; Swift, R. M.; Abrams, D. B.; Shiffman, S.; Paty, J. A. Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol. Clin. Exp. Res., 2008, 32(1), 58-66. (Pubitemid 350293891)
213. Spanagel, R. and Kiefer, F. Drugs for relapse prevention of alcoholism: ten years of progress. Trends Pharmacol. Sci., 2008, 29(3), 109-115.
214. Yamamoto, T.; Nair, P.; Largent-Milnes, T. M.; Jacobsen, N. E.; Davis, P.; Ma, S. W.; Yamamura, H. I.; Vanderah, T. W.; Porreca, F.; Lai, J.; Hruby, V. J. Discovery of a Potent and Efficacious Peptide Derivative for delta/mu Opioid Agonist/Neurokinin 1 Antagonist Activity with a 2′,6′-Dimethyl-l- Tyrosine: In vitro, In vivo, and NMR-Based Structural Studies. J. Med. Chem., 2011, 54(7), 2029-2038.